Ampliphi Biosciences Corp Share Price Nyse
Equities
APHB
US03211P2020
Biotechnology & Medical Research
Sales 2024 * | 4.54M 359M | Sales 2025 * | 2.75M 218M | Capitalization | 101M 7.95B |
---|---|---|---|---|---|
Net income 2024 * | -72M -5.7B | Net income 2025 * | -67M -5.3B | EV / Sales 2024 * | 22.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.5 x |
P/E ratio 2024 * |
-1.46
x | P/E ratio 2025 * |
-2.14
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.72% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 10/07/23 |
Richard Rychlik
DFI | Director of Finance/CFO | 68 | 04/09/23 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 11/02/20 | |
Joseph Patti
BRD | Director/Board Member | 60 | 08/05/19 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 31/03/21 |
1st Jan change | Capi. | |
---|---|---|
+30.87% | 52.73B | |
+37.80% | 39B | |
-9.30% | 38.52B | |
+25.92% | 30.38B | |
-11.17% | 26.39B | |
+10.83% | 26.08B | |
+45.01% | 14.15B | |
+33.26% | 12.6B | |
-5.44% | 11.51B |